Skip to content

Shattuck Labs, Inc. STTK Convertible Preferred Stock Outstanding Shares

Convertible Preferred Stock Outstanding Shares at other companies

Zymeworks logo
ZymeworksZYME
Nektar Therapeutics logo
Nektar TherapeuticsNKTR

Other financials

Income statement

See full
Revenue-
Operating income-$15.5M-8.0%
Net income-$14.8M-7.8%
EPS (diluted)-$0.13+51.9%

Balance sheet

See full
Cash & equivalents$90.4M+48.5%
Total debt$2.9M-9.5%
Total equity$95.8M+41.8%
Total assets$102.1M+32.3%

Cash flow

See full
Operating cash flow-$13.4M-11.6%
CapEx$63.0K
Free cash flow-$13.5M-12.1%

Valuation

See full
Market cap$564.45M+1,131%
Enterprise value$476.92M-4,119%
P/S564.5×+554×

Profitability

See full
Operating margin-5,266.4%-9,520pp
Net margin-4,987.4%-8,966pp
FCF margin-4,140.8%-7,144pp

Returns & leverage

See full
Return on equity-61%-8.0pp
Debt / equity0.0×
Current ratio22.1×+13.0×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesOutstanding.

The official record: Shattuck Labs, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Shattuck Labs, Inc.'s convertible preferred stock outstanding shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Shattuck Labs, Inc.'s convertible preferred stock outstanding shares?
Shattuck Labs, Inc. (STTK) reported convertible preferred stock outstanding shares of 0 in Q1 2026.
What does convertible preferred stock outstanding shares mean?
This represents the total number of preferred equity shares that can be converted into common stock at the holder's discretion. These shares often carry liquidation preferences and represent a significant component of the company's capital structure. Monitoring this is essential for calculating fully diluted share counts and understanding the potential impact of conversion on equity ownership.